You are here:

Archived: bevacizumab (Avastin)

Advice

following a full submission:

bevacizumab (Avastin®) is not recommended for use within NHS Scotland.

Indication under review: bevacizumab in combination with carboplatin and paclitaxel is indicated for the front-line treatment of advanced (International Federation of Gynaecology and Obstetrics [FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.

In two phase lll studies, bevacizumab in combination with carboplatin and paclitaxel significantly increased progression free survival compared with carboplatin and paclitaxel alone in patients with advanced ovarian cancer.

The submitting company’s base case economic analysis was based on an unlicensed dose of the medicine and this is not within the SMC remit. For the sensitivity analysis using the licensed dose, the submitting company’s justification of the treatment’s cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust economic analysis to gain acceptance by SMC.
 

Drug Details

Drug Name: bevacizumab (Avastin)
SMC Drug ID: 806/12
Manufacturer: Roche
Indication: bevacizumab in combination with carboplatin and paclitaxel is indicated for the front-line treatment of advanced (International Federation of Gynaecology and Obstetrics [FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 8 October 2012

Current Advice

Resubmission 9 November 2015

Archived Advice

Resubmission 12 January 2015

Back